14) Provisions, Contingent Liabilities & Contingent
Assets:
The company recognizes as provisions, the
liability being present obligations arising from
past events, the settlement of which is expected
to result in outflow of resources and which can
be measured only by using a substantial degree
of estimation. Contingent liabilities are disclosed
by way of a note to the financial statement after
careful evaluation by the management of the
facts and legal aspect of the matters involved.
Contingent assets are being neither recognized
nor disclosed.
15) Curent Assets, Loans And Avances
The balance under items of Sundry Debtors,
Loans and Advances and current liabilities are
subject to confirmation and reconciliation and
consequential adjustments, wherever applicable.
However, in the opinion of the Management, the
realisable value of the current assets, loans and
advances in the ordinary course of business
will not be less than the value at which they are
stated in the Balance Sheet.
16) Cash Flow
Cash flows are reported using the indirect
method, whereby profit before tax is adjusted
for the effects of transactions of non-cash
nature, any deferrals or accruals of past or
future operating cash receipts or payments and
item of income or expenses associated with
investing or financing cash flows. Cash flows
from operating, investing and financing activities
of the Company are segregated, accordingly.
17) Segment Reporting
As the company is dealing in only one segment
i.e. manufacturing industry, API, hence segment
reporting is not applicable. Company does not
have distinguishable component of an enterprise
that is engaged in providing an individual
product or service or group of related product or
services and that is subject to risks and returns
that are different from those of other business
segment.
4 Terms & Right attached to Equity Shares
Equity Shares: The company has only one class of equity shares having a par value of Rs.10/- each. Each
shareholder is eligible for one vote per share held. The dividend if any proposed by the Board of Director is
subject to approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend.
In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company
after distribution of all preferential amounts and payment of preference shareholders, in proportionate to their
shareholding.
28.1 In the opinion of the Board of Directors, the current assets, loans and advances are approximately of the same
value if realised in the ordinary courses of business and the provision for all known liabilities is adequately made and
not in excess of the amount reasonably consider necessary.
28.2 The figures and groupings of the previous year are re-grouped/reclassified whenever necessary so as to make
them comparable with the current year.
28.3 The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms
of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
28.4 No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any
other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities
("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend
or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries).
28.5 The Company has not received any fund from any party(s) (Funding Party) with the understanding that the
Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf
of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate
Beneficiaries.
28.6 Paise have been round off to the nearest rupee amount.
The Board of Directors of the Company, at its meeting held on 11th January 2025, has approved the slump sale of
its existing business unit comprising land, building, plant & machinery, specific current assets and current liabilities,
which contributed approximately 99.44% of the revenue from operations during the previous financial year. The
transaction, subject to necessary shareholder and regulatory approvals, is expected to be completed by December
2025. The buyer is a related party, and the transaction is proposed to be at arm's length, supported by independent
valuation reports.
Further, the Company has also approved to alter its business objects and venture into new business verticals including
clean and renewable energy, real estate and construction, and capital market investments.
The management has evaluated the impact of these strategic changes on the going concern assumption. Although
the existing core business will cease post-sale, the management is confident of the Company's ability to continue as
a going concern based on:
Availability of adequate financial resources post slump sale (approx. ?95 crores),
Concrete plans to deploy proceeds into viable and growing sectors,
Continuation of corporate existence and operations in new business lines,
Ongoing steps to obtain requisite approvals and realign operations accordingly.
Accordingly, the financial statements have been prepared on a going concern basis. However, the Company is in the
process of transitioning its business model, and the successful execution of new ventures remains dependent on
various internal and external factors, including regulatory approvals and market conditions.
Nature of CSR activities :- Rs 7.00 Lacs Expenditure incurred for CSR activity with Shree Sarveshwar Gau Dham
Trust, Kobadi, Dist-Bhavnagar, Gujarat, India in the area of promoting animal welfare activities and Rs 25.00 Lacs
Expenditure incurred for CSR activity with Gohilwad Leauva Patidar Kelavani Mandal, C/o G M Vanani Niru Patel
Boarding, Plot No.1992, Near Shamaldas College Gate, Waghawadi Road, Bhavnagar-364002 under the area of
promoting education among rural students and livelihood enhancement project named "Annapurna".
No any contribution made to a trust controlled by the company in relation to CSR expenditure
As per our report of even dated.
For, Sarupria Somani & Associates For and on behalf of Board of Directors of
Firm Regn. No.010674C Par Drugs and Chemicals Limited
Chartered Accountants
Sd/- Sd/-
Mr. Falgun V. Savani Mr. Jigneshbhai V. Savani
(Chairman & Managing Director) Director & CEO
Sd/- (DIN - 00198236) (DIN - 00198203)
Miral Mehta (Partner)
M.No.145361 Sd/- Sd/-
UDIN - 25145361BMLKCF4039 Chintan P Chauhan Sanket B Trivedi (CS)
(CFO) (M.No.- 51758)
|